Clinical trials: Cardiac Hypertrophy
Myocardial Bridging, Obstructive Hypertrophic Cardiomyopathy
Myocardial Bridging in Obstructive Hypertrophic Cardiomyopathy
This study investigated the impact of myocardial bridging (MB) and its characteristics on preoperative atrial fibrillation and survival in patients with obstructive hypertrophic cardiomyopathy (oHCM).
- Conditions
- Myocardial Bridging, Obstructive Hypertrophic Cardiomyopathy, Atrial Fibrillation (AF)
- Trial name
- MB in oHCM (NCT06598995)
- Testing
- Coronary artery bypass grafting or unroofing
- Where
- China
- Volunteers
- 968 people
- Sponsor
- Chinese Academy of Medical Sciences, Fuwai Hospital
Healthy Adults (Full Study and Extension Phase), Hypertrophic Cardiomyopathy or Dilated Cardiomyopathy
A Pilot Project Exploring the Impact of Whole Genome Sequencing in Healthcare
The MedSeq™ Project seeks to explore the impact of incorporating information from a patient's whole genome sequence into the practice of clinical medicine.
- Trial name
- NCT01736566
- Testing
- Family History + Whole Genome Sequencing, Family History Only
- Where
- United States
- Volunteers
- 213 people, healthy volunteers welcome
- Sponsor
- Brigham and Women's Hospital
Sudden Cardiac Arrest, Sudden Arrhythmic Death Syndrome
Hearts in Rhythm Organization (HiRO)National Registry and Bio Bank
The Hearts in Rhythm Organization (HiRO) is a national network of Canadian researchers/clinicians, working towards a better understanding of the rare genetic causes of sudden cardiac death (SCD).
- Conditions
- Sudden Cardiac Arrest, Sudden Arrhythmic Death Syndrome, Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC), Long QT Syndrome (LQTS)
- Trial name
- HiRO (NCT04189822)
- Where
- Canada
- Volunteers
- 10,000 people
- Sponsor
- University of British Columbia
Lumbar Spinal Stenosis, Cardiac Amyloidosis
Analysis of Lumbar Spine Stenosis Specimens for Identification of Transthyretin Cardiac Amyloidosis
Primary objective: To identify older adults with transthyretin cardiac amyloidosis (ATTR-CA) early in the course of the illness, at a time when disease modifying therapies are most effective.
- Conditions
- Lumbar Spinal Stenosis, Cardiac Amyloidosis, ATTR Amyloidosis Wild Type, ATTR Gene Mutation
- Trial name
- NCT06034405
- Testing
- Tc99-PYP or Tc99-HDMP Scan
- Where
- 6 sites in United States
- Volunteers
- 1,663 people, healthy volunteers welcome
- Sponsor
- Columbia University
HCM - Hypertrophic Cardiomyopathy
Automated Reports Generation of Cardiovascular Magnetic Resonance Imaging
The goal of this observational study is to evaluate the accuracy, completeness, and clinical consistency of large language model-generated cardiac magnetic resonance (CMR) imaging reports compared with expert radiologist reports…
- Trial name
- NCT07340762
- Testing
- large lanuage model
- Where
- China
- Volunteers
- 20,000 people, healthy volunteers welcome
- Sponsor
- Chinese Academy of Medical Sciences, Fuwai Hospital
Aortic Stenosis
Aortic Stenosis and PhosphodiEsterase iNhibition With Aortic Valve Replacement (ASPEN-AVR): A Pilot Study
Currently, aortic stenosis (AS) is considered a "surgical disease" with no medical therapy available to improve any clinical outcomes, including symptoms, time to surgery, or long-term survival.
- Trial name
- ASPEN-AVR (NCT01272388)
- Testing
- Tadalafil
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Washington University School of Medicine
Cardiomyopathy, Hypertrophic Obstructive, Minimally Invasive Surgery
Efficacy and Safety of Thoracoscopic Morrow Surgery in the Treatment of Hypertrophic Obstructive Cardiomyopathy
This single-center, prospective, open-label, randomized, controlled clinical trial is designed to assess the efficacy and safety of the Thoracoscopic Morrow procedure in the treatment of hypertrophic obstructive cardiomyopathy.
- Trial name
- NCT06391788
- Testing
- thoracoscopic Morrow surgery, modified Morrow surgery
- Where
- China
- Volunteers
- 132 people
- Sponsor
- China National Center for Cardiovascular Diseases
Obstructive Hypertrophic Cardiomyopathy (oHCM)
Ademetionine in Obstructive Hypertrophic Cardiomyopathy
This study is a multicenter, double-blind, randomized controlled Phase 2 trial designed to evaluate the safety and efficacy of Ademetionine in patients with obstructive hypertrophic cardiomyopathy (oHCM).
- Trial name
- NCT07367724
- Testing
- Ademetionine 1,4-Butanedisulfonate
- Where
- 3 sites in China
- Volunteers
- 44 people
- Sponsor
- China National Center for Cardiovascular Diseases
Hypertension, Left Ventricular Hypertrophy
Aliskiren in Combination With Losartan Compared to Losartan on the Regression of Left Ventricular Hypertrophy in Overweight Patients With Essential Hypertension
To compare the efficacy and safety of aliskiren in combination with losartan compared to losartan on the regression of the increased size of the left ventricle in overweight patients with high blood pressure.
- Conditions
- Hypertension, Left Ventricular Hypertrophy, Overweight
- Trial name
- ALLAY (NCT00219141)
- Testing
- Aliskiren 150/300 mg, Losartan 50/100 mg
- Where
- 9 sites in United States, Argentina and 7 more
- Volunteers
- 460 people
- Sponsor
- Novartis Pharmaceuticals
Hypertrophic Cardiomyopathy
Viz HCM (ECG Assist) Utilization Workflow Pilot
This is a prospective, open-label, multi-center workflow pilot. Viz HCM will be implemented at each participating site and all conforming incoming ECG recordings within a 6-month enrollment period will be analyzed using Viz HCM.
- Trial name
- NCT06600256
- Testing
- Viz HCM ECG Review, Baseline Effectiveness Cohort
- Where
- 5 sites in United States
- Volunteers
- 217 people
- Sponsor
- Viz.ai, Inc.
End Stage Renal Disease
Risk Factors for Coronary Artery Calcification and Left Ventricular Hypertrophy in Hemodialysis Patients
Individuals with kidney disease are at a higher risk for heart and vascular diseases, including heart attacks and strokes, than those with normal kidney function.
- Trial name
- NCT01427374
- Where
- 4 sites in United States, Canada
- Volunteers
- 30 people
- Sponsor
- University of Alberta
Cardiomyopathy, Hypertrophic
Pacemaker Therapy for Drug-refractory Symptoms in Mid-cavity Hypertrophic Cardiomyopathy
The main aim of this study is to assess the acute effects of a pacemaker on reducing abnormally high intracavity pressures in the hearts of patients with mid-cavity obstructive hypertrophic cardiomyopathy (HCM).
- Trial name
- NCT03450252
- Testing
- Active pacing, Back-up pacing
- Where
- United Kingdom
- Volunteers
- 17 people
- Sponsor
- Barts & The London NHS Trust
Masked Hypertension
Antihypertensive Treatment in Masked Hypertension
The primary purpose of the study is to estimate the target organ protection after 12 months of antihypertensive treatment in masked hypertension patients with at least one kind of target organ damage (left ventricular…
- Trial name
- ANTI-MASK (NCT02893358)
- Testing
- Allisartan Isoproxil
- Where
- China
- Volunteers
- 320 people
- Sponsor
- Yan Li
Peripheral Vascular Diseases, Heart Failure
Peripheral Artery Disease in Vastmanland
The main purposes of this study are: to describe the prevalence and degree of reduced left ventricular function and hypertrophy in patients with peripheral arterial disease in comparison to controls from the general population…
- Conditions
- Peripheral Vascular Diseases, Heart Failure, Ventricular Dysfunction
- Trial name
- PADVa (NCT01452165)
- Where
- Sweden
- Volunteers
- 457 people
- Sponsor
- Uppsala University
Cushing's Syndrome Cardiomyopathy
Endocrine Cardiomyopathy in Cushing Syndrome: Response to Cyclic GMP PDE5 inhibitOrs
Pathophysiology of Cushing's Syndrome (CS) cardiomyopathy is yet unclear and a specific treatment have not been indicated. It was already demonstrated the positive impact of phosphodiesterase type 5A (PDE5A) inhibition in several…
- Trial name
- ERGO (NCT02611258)
- Testing
- Tadalafil
- Where
- Italy
- Volunteers
- 18 people
- Sponsor
- Andrea M. Isidori
PCOS, Cardiovascular Disease
Fish Oil, Metformin and Heart Health in PCOS
Women with Polycystic Ovary Syndrome (PCOS) have high testosterone levels which is associated with altered insulin-glucose metabolism and an adverse blood lipid profile, predisposing them to the development of Type II Diabetes…
- Conditions
- PCOS, Cardiovascular Disease, Atherosclerotic Cardiovascular Disease, Atherosclerotic Plaque
- Trial name
- NCT06424860
- Testing
- Fish oil, Metformin, Fish Oil and Metformin
- Where
- 3 sites in Canada
- Volunteers
- 146 people
- Sponsor
- University of Alberta
Long QT Syndrome, Sinus Bradycardia
A Study to Evaluate Accuracy and Validity of the Chang Gung ECG Abnormality Detection Software
"Chang Gung ECG Abnormality Detection Software" is a is an artificial intelligence medical signal analysis software that detect whether patients have abnormal ECG signals of 14 diseases by static 12-lead ECG.
- Conditions
- Long QT Syndrome, Sinus Bradycardia, Sinus Tachycardia, Premature Atrial Complexes
- Trial name
- NCT05903313
- Testing
- Chang Gung ECG Abnormality Detection Software
- Where
- Taiwan
- Volunteers
- 4,306 people
- Sponsor
- Chang Gung Memorial Hospital
Cardiomyopathy, Hypertrophic Cardiomyopathies
French Registry: Late Gadolinium Enhancement in Hypertrophic Cardiomyopathy
This study aims to create a registry of patients with hypertrophic cardiomyopathy, a condition characterized by excessive thickening of the heart muscle. This disease can sometimes lead to serious complications.
- Trial name
- HCM-LGE (NCT07428031)
- Volunteers
- 5,000 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Hypertrophic Cardiomyopathy (HCM)
HCMR Re-Imaging Study
This study aims to learn what might predict heart problems (like sudden death from a fast heart rhythm or heart failure) in people with a genetic condition called hypertrophic cardiomyopathy (HCM).
- Trial name
- NCT07054073
- Testing
- None - observational study
- Where
- 8 sites in United States, United Kingdom
- Volunteers
- 314 people
- Sponsor
- Christopher Kramer
Hypertrophic Cardiomyopathy
Machine Learning Approach Based on Echocardiographic Data to Improve Prediction of Cardiovascular Events in Hypertrophic Cardiomyopathy
Hypertrophic cardiomyopathy is a pathology with a highly variable course, ranging from patients who are asymptomatic throughout their lives to those who experience sudden death and/or terminal heart failure.
- Trial name
- 2022PI172 (NCT06256913)
- Where
- 2 sites in France
- Volunteers
- 870 people
- Sponsor
- Pr. Nicolas GIRERD